A previous open‐label phase III trial revealed that pembrolizumab monotherapy is an effective first‐line treatment for patients with NSCLC with high programmed death‐ligand 1 (PD‐L1) expression (≥50% of tumor cells).2 The gene discussed is CD274; the disease is non-small cell lung carcinoma.